Connetics Dermatitis Drug Succeeds On Second Trial

Connetics Corp. said its experimental drug for seborrheic dermatitis, which had been rejected by U.S. regulators due to concerns about its effectiveness, showed favorable results in another late-stage trial.
The U.S. Food and Drug Administration in November 2004 rejected the product, called Extina, after it failed in an earlier Phase III trial to prove superior to a placebo foam for the condition.
In the latest four week trial, however, Connetics said 56 percent of patients treated with Extina had an improvement in symptoms, compared with 42 percent of those receiving the placebo foam, a difference that was highly statistically significant.